Rege Nephro
Kyoto, Japan· Est.
A regenerative medicine company using iPS cell technology to develop novel therapies for kidney diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $3.3B
AI Company Overview
A regenerative medicine company using iPS cell technology to develop novel therapies for kidney diseases.
NephrologyRare Disease
Technology Platform
iPS cell differentiation platform for generating renal progenitor cells including nephron progenitor cells (NPCs), erythropoietin-producing cells, and ureteral blast cells.
Opportunities
Large unmet need in chronic kidney disease treatment with over 13 million patients in Japan alone and global dialysis costs creating substantial market opportunity for effective regenerative therapies.
Risk Factors
High technical risk associated with iPS cell differentiation and cell therapy manufacturing, clinical translation challenges, and competition from other regenerative medicine approaches and pharmaceutical interventions.
Competitive Landscape
Competes with other regenerative medicine companies developing cell therapies for kidney disease, but differentiates through proprietary iPS cell differentiation methods for nephron progenitor cells and strong academic foundation from Kyoto University's iPS cell research.